The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected to provide growth opportunities for players operating in the immunofluorescence assays market in the coming years. However, quality concerns over antibodies are the major challenge in this market.
The kits segment accounted for the highest growth rate in the Immunofluorescence assay market, by product, during the forecast period The Immunofluorescence assay market is segmented into reagents, instruments, antibodies, kits, and consumables and accessories.The kits segment accounted for the highest growth rate in the Immunofluorescence assay market in 2020.
The demand for complete solutions from a single provider, like closed-system reagents with calibrated measurements of the required quantity of reagents and controls, among CROs, academic institutes, and research institutes is growing, contributing to this segment’s high growth rate.
Indirect immunofluorescence segment accounted for the highest CAGR Based on type, the immunofluorescence assays market is segmented into indirect immunofluorescence and direct immunofluorescence.In 2020, indirect immunofluorescence accounted for accounted for the highest growth rate.
The major factors driving the growth of this segment are its advantages such as sensitivity, flexibility, better amplification of the signal, and lower cost over direct immunofluorescence.
Cancer segment accounted for the highest CAGR Based on disease, the immunofluorescence assays market is segmented into cancer, infectious diseases, autoimmune diseases, cardiovascular diseases, and other diseases.In 2020, the cancer segment accounted for the highest growth rate.
Increasing prevalence of cancer globally and the widespread adoption of immunofluorescence techniques for the study and diagnosis of cancer are the major factors driving this segment’s growth.
Hospitals & Diagnostic Centers segment accounted for the highest CAGR Based on end user, the immunofluorescence assays market is segmented intopharmaceutical & biotechnology companies, academic & research institutes, hospitals & diagnostics centers, and contract research organizations.In 2020, the hospitals & diagnostics centers segment accounted for the highest growth rate.
This can be attributed to the rising number of cases for various diseases coupled with the increasing number of hospitals worldwide are the major driving factors for this segment’s growth.
Asia Pacific: The fastest-growing country in the Immunofluorescence assay market The Immunofluorescence assay market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa.Asia Pacific is projected to register the highest CAGR during the forecast period.
Factors such as improving healthcare infrastructure, increasing healthcare spending, and favorable government initiatives are driving the growth of the immunofluorescence assay market in Asia Pacific.
The primary interviews conducted for this report can be categorized as follows: • By Company Type: Tier 1 - 32%, Tier 2 - 44%, and Tier 3 - 24% • By Designation: C-level - 30%, D-level - 34%, and Others - 36% • By Region: North America- 50%, Europe- 32%, APAC-10%, RoW- 8%
Lists of Companies Profiled in the Report: • Thermo Fisher Scientific, Inc. (US) • Abcam plc (UK) • Bio-Rad Laboratories, Inc. (US) • PerkinElmer Inc. (US) • Merck KGaA (Germany) • Werfen Company (Spain) • Cell Signaling Technology, Inc. (US) • MEDIPAN GmbH (Germany) • Sino Biological, Inc. (China) • Danaher Corporation (US) • Maravai LifeSciences (US) • Enzo Biochem, Inc. (US) • Becton, Dickinson and Company (US) • Olympus Corporation (Japan) • Nikon Corporation (Japan) • Bruker Corporation (US) • Agilent Technologies (US) • Zyagen, Inc. (US) • Cellabs (Australia) • J. Mitra & Co. Pvt. Ltd. (India) • Abnova Corporation (Taiwan) • EpiGentek Group (US) • Elabscience, Inc. (US) • AESKU GROUP GmbH (Germany) • MaxVision Biosciences Inc. (Canada)
Research Coverage: This report provides a detailed picture of the Immunofluorescence assay market.It aims at estimating the size and future growth potential of the market across different segments, such as the product, type, disease, end user, and region.
The report also includes an in-depth competitive analysis of the key market players, along with their company profiles, recent developments, and key market strategies.
Key Benefits of Buying the Report: The report will help market leaders/new entrants by providing them with the closest approximations of the revenue numbers for the overall Immunofluorescence assay market and its subsegments.It will also help stakeholders better understand the competitive landscape and gain more insights to better position their business and make suitable go-to-market strategies.
This report will enable stakeholders to understand the market’s pulse and provide them with information on the key market drivers, restraints, trends, opportunities, and challenges.
Our reports have been used by over 10K customers, including:
The global dementia drugs market was valued at approximately USD 12,736.06 million in 2020 and is expected to witness a revenue of USD 19,655.10 million in 2026, with a CAGR of 7.87% over the forecast period. The outbreak of the COVID-19 pandemic is expected to have a significant impact on the Dementia drugs market. According to a research...
The Smart Label Market is expected to grow at a CAGR of 13.2% over the forecast period (2021-2026). Smart labels are becoming one of the most popular technologies across the retail, healthcare, and logistics sectors, and are viewed as an ideal means to achieve greater efficiencies and profitability while providing the authenticity of an item...
The global dPCR and qPCR market size is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0%. The growth of this market is driven majorly by factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments,...
In-depth Analysis and Data-driven Insights on the Impact of COVID-19 Included in this Global IV and Oral Iron Drugs Market Report
The global IV and oral iron drugs market by revenue is expected to grow at a CAGR of 11.6% during the period 2021–2026.
The global IV and oral iron drugs market is expected to grow due to the prevalence...
The oxygenators market was valued at USD 207 million in 2020, and it is poised to grow at a CAGR of 5.4% during the forecast period, 2021-2026, to reach USD 297 million by 2026. To cope up with the current COVID-19 situation, companies are increasing the production of oxygenators globally to support the adoption of ECMO procedures for...
The anti-money laundering solution market was valued at US$ 1,503.99 million in 2019 and is projected to reach US$ 5,866.51 million by 2027; it is expected to grow at a CAGR of 16.2% from 2020 to 2027. Transaction monitoring is a crucial procedure and key control in anti-money laundering (AML) and countering the financing of terrorism (AML/CFT)...
The global patient access solutions market is projected to reach USD 2.4 billion by 2025 from USD 1.6 billion in 2020, at a CAGR of 8.5%. Increasing patient volume and subsequent growth in the demand for health insurance, the growing importance of denials management, declining reimbursement rates, increase in the volume of unstructured data...
296 pages •
By The Business Research Company
• Mar 2021
Vascular Endothelial Growth Factor (VEGF) Inhibitor Global Market Opportunities And Strategies To 2030: COVID 19 Impact And Recovery provides the strategists, marketers and senior management with the critical information they need to assess the global vascular endothelial growth factor (VEGF) inhibitor market. Description: Where...
The specialty PACS market is anticipated to register a CAGR of 4.87%, over the forecast period. - The significant factors attributing to the studied market’s growth is the growing use of visualization and opting for greater collaboration between IT structures and imaging modalities, and diverse medical fields that have been gradually...
The market is primarily driven by the growing prevalence of chronic diseases such as diabetes, respiratory diseases and cancer. Furthermore, the growing geriatric population and technological advances in drug delivery systems is projected to boost market growth over the forecast period. Moreover, expanding applications of drug device combination...
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.